Leukemia | Topics

Unmet Needs and Future Directions in CLL
June 02, 2022

Drs Bishop and Bank close by outlining remaining unmet needs in CLL, emerging regimens, and hopes for the future of care.

Key Takeaways and Clinical Implications
June 02, 2022

Michael R. Bishop, MD, and Bruce B. Bank, MD, summarize key takeaways from the ELEVATE-RR study and discuss the clinical implications of using BTK inhibitors in patients with CLL.

ELEVATE-RR: Safety Data
June 02, 2022

Drs Bishop and Bank discuss ELEVATE-RR safety data.

Cross Q&A: The Memorial Sloan-Kettering Mavericks
May 27, 2022

The Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.

Outcome Determination for Adolescents and Young Adults with ALL
May 27, 2022

Xiaoli Mi, MD, presents data from a paper in Blood on the determination of outcomes for adolescents and young adults with ALL.

Pediatric-Inspired Chemotherapy Incorporating Pegaspargase in Adults with Ph-ALL
May 27, 2022

Varun Narendra, MD, describes a clinical trial that studied whether pediatric-inspired ALL regimens could be used in older adults with Philadelphia chromosome–positive ALL.

Recap: Finding the Optimal Dose of Ponatinib for Chronic Phase CML
May 27, 2022

Experts discuss use of ponatinib in chronic myeloid leukemia and optimal dosing.

ELEVATE-RR: Efficacy Data
May 24, 2022

Experts discuss efficacy data from the ELEVATE-RR trial on the Bruton tyrosine kinase inhibitors acalabrutinib vs ibrutinib.

Patient Characteristics in ELEVATE-RR
May 24, 2022

Dr Bishop comments on the characteristics of the patients with CLL who were enrolled in the ELEVATE-RR trial.

A Pediatric Regimen for Older Adults and Adolescents with ALL: CALGB 10403 Study
May 23, 2022

Varun Narendra, MD, presents the CALGB 10403 clinical trial on the use of a pediatric regimen in older adolescents and young adults with ALL.